1. Home
  2. CNSP vs CWD Comparison

CNSP vs CWD Comparison

Compare CNSP & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNS Pharmaceuticals Inc.

CNSP

CNS Pharmaceuticals Inc.

N/A

Current Price

$3.07

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Logo CaliberCos Inc.

CWD

CaliberCos Inc.

N/A

Current Price

$1.47

Market Cap

10.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CNSP
CWD
Founded
2017
2009
Country
United States
United States
Employees
4
81
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
10.0M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
CNSP
CWD
Price
$3.07
$1.47
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
18.4K
35.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$51,119,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$26.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.20
52 Week High
$10.59
$46.21

Technical Indicators

Market Signals
Indicator
CNSP
CWD
Relative Strength Index (RSI) 34.77 61.83
Support Level $0.86 $1.11
Resistance Level $8.89 $1.54
Average True Range (ATR) 0.29 0.09
MACD 0.11 0.03
Stochastic Oscillator 23.38 95.83

Price Performance

Historical Comparison
CNSP
CWD

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

About CWD CaliberCos Inc.

CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.

Share on Social Networks: